Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VTAK vs CLPT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VTAK Captures Overall Composite Edge (58.1 HOLD vs 40.0 SELL), While CLPT Leads 4–1 on Growth & Valuation Pillars

VTAK Overall Winner 6-Pillar Tally: VTAK 1 – 4 CLPT (1 Tie) Matrix Metrics: VTAK 5 – 5 CLPT

As of Nov 16, 2026, Catheter Precision, Inc. (VTAK) captures the overall head-to-head institutional edge over ClearPoint Neuro, Inc. (CLPT) on higher Unified Composite conviction (58.1/100 HOLD vs. 40.0/100 SELL) after splitting the core matrix 5–5 (led by Options & Positioning), while CLPT wins 4–1 across the 6-pillar growth and valuation breakdown. VTAK trades at $0.15 (N/M Forward P/E, -388.1% operating margin) versus CLPT at $8.30 (12.1x Forward P/E, -66.6% operating margin).

  • Growth vs. Quality Trade-Off: VTAK earns the overall head-to-head edge with a stronger Unified Composite Score (58.1/100 HOLD vs. CLPT 40.0/100 SELL) and 0.19β · 76% Vol risk profile, whereas CLPT leads top-line expansion (+36.3% YoY revenue growth, 0.60x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: VTAK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2); meanwhile CLPT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VTAK vs CLPT
VTAK NYSE American Head-to-Head Winner
Catheter Precision, Inc.
Surgical & Medical Instruments & Apparatus
$0.15
-0.66% 1D
Market Cap $548,639
TTM Revenue $1.9M
Forward P/E N/M
Beta / 30D Vol 0.19β · 76% Vol
Unified Composite Score
58.1 / 100 HOLD
Tech 72.0 Fund 70.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -53.4%), weak momentum, RSI 33
RSI-14: 33.2 · SMA20: $0.16 · SMA50: $0.21
CLPT NASDAQ
ClearPoint Neuro, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$8.30
-2.12% 1D
Market Cap $271.8M
TTM Revenue $45M
Forward P/E 12.1x
Beta / 30D Vol 1.90β · 85% Vol
Unified Composite Score
40.0 / 100 SELL
Tech 30.0 Fund 50.0 Flow 64.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.5%), weak momentum, RSI 37
RSI-14: 36.6 · SMA20: $9.36 · SMA50: $11.14

6-Pillar Scorecard Institutional Category Breakdown (VTAK 1 – 4 CLPT)

Columns: Metric · VTAK · CLPT
1. Valuation Multiples CLPT
Forward P/E N/M 12.1x
Trailing P/E N/M 12.1x
PEG Ratio N/M 0.60x
EV / Revenue 0.3x 6.6x
2. Growth & Scale CLPT
Revenue Growth (YoY) +380.7% +36.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1.9M $45M
Market Cap $548,639 $271.8M
3. Profitability & Quality CLPT
Gross Margin 47.7% 61.4%
Operating Margin -388.1% -66.6%
Net Profit Margin 0.0% -79.4%
Return on Equity (ROE) -111.3% -167.5%
4. Balance Sheet & Cash Flow CLPT
Cash Generation (TTM) -$10M EBITDA -$33M
Cash Flow Margin N/A -73.0%
Net Cash / Leverage $4.87 Book/Sh · -111.3% ROE $28M Net Debt (2.70x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VTAK
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 68.7% (2nd %ile)
Put/Call OI Skew N/A 1.17x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VTAK (5) vs CLPT (5)
Institutional Metric VTAK CLPT Criterion Row Edge
Market Capitalization
Scale
$548,639 $271.8M Larger Scale CLPT
Trailing P/E Ratio
Valuation
N/M 12.1x Lower Multiple CLPT
Forward P/E Ratio
Valuation
N/M 12.1x Lower Multiple CLPT
Revenue Growth (YoY)
Growth
+380.7% +36.3% Higher Growth VTAK
Operating Margin (TTM)
Profitability
-388.1% -66.6% Higher Margin CLPT
Net Profit Margin
Profitability
0.0% -79.4% Higher Margin VTAK
Return on Equity (ROE)
Capital Efficiency
-111.3% -167.5% Higher ROE VTAK
52-Week Range Position
Momentum
1% ($0–$3) 2% ($8–$20) Stronger Trend CLPT
Beta / 30D Volatility
Risk Regime
0.19β · 76% Vol 1.90β · 85% Vol Lower Realized Risk VTAK
Unified Institutional Score
Composite Signal
58.1 / 100 (HOLD) 40.0 / 100 (SELL) Higher Composite VTAK
Trailing 12M Revenue (USD)
Operating Scale
$1.9M $45M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
47.7% 61.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.3x EV/Rev 0.60x PEG · 6.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$10M EBITDA ($4.87 Book/Sh · -111.3% ROE) -$33M ($28M Net Debt (2.70x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CLPT +0.9 pp
VTAK: -24.76% · CLPT: -23.86%
3M Horizon CLPT +40.82 pp
VTAK: -80.29% · CLPT: -39.47%
6M Horizon CLPT +100.04 pp
VTAK: -83.76% · CLPT: +16.28%
1Y Horizon CLPT +62.92 pp
VTAK: -92.63% · CLPT: -29.71%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VTAK Revenue CLPT Revenue VTAK Op. Margin CLPT Op. Margin Margin Leader
FY2018 $10M $10M -498.0% -71.4% CLPT
FY2019 $10M $10M -801.9% -41.0% CLPT
FY2020 $0M $10M -13668.3% -48.5% CLPT
FY2021 $0M $20M -133027.3% -82.1% CLPT
FY2022 $0M $20M -192578.6% -79.5% CLPT
FY2023 $0M $20M -17674.0% -93.7% CLPT
FY2024 $0M $30M -2676.9% -62.9% CLPT
FY2025 $0M $40M -2581.6% -65.4% CLPT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VTAK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VTAK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CLPT BREAKDOWN
98d in phase · OBV DISTRIBUTION
Current IV 68.7%
IV Percentile 2nd %ile
Put/Call OI Skew 1.17x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact CLPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VTAK Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $548,639 market capitalization and -388.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CLPT Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $271.8M market capitalization and -66.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VTAK vs CLPT Key Questions & Quantitative Answers

As of Nov 16, 2026, Catheter Precision, Inc. (VTAK) captures the overall head-to-head institutional edge over ClearPoint Neuro, Inc. (CLPT) on higher Unified Composite conviction (58.1/100 HOLD vs. 40.0/100 SELL) after splitting the core matrix 5–5 (led by Options & Positioning), while CLPT wins 4–1 across the 6-pillar growth and valuation breakdown. VTAK trades at $0.15 (N/M Forward P/E, -388.1% operating margin) versus CLPT at $8.30 (12.1x Forward P/E, -66.6% operating margin). Growth vs. Quality Trade-Off: VTAK earns the overall head-to-head edge with a stronger Unified Composite Score (58.1/100 HOLD vs. CLPT 40.0/100 SELL) and 0.19β · 76% Vol risk profile, whereas CLPT leads top-line expansion (+36.3% YoY revenue growth, 0.60x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VTAK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2); meanwhile CLPT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CLPT leads the Growth & Scale pillar: VTAK posts +380.7% YoY revenue growth and +0.0% YoY earnings growth on $1.9M TTM revenue (47.7% gross margin, -388.1% operating margin), compared with CLPT at +36.3% YoY revenue growth and +0.0% YoY earnings growth on $45M TTM revenue (61.4% gross margin, -66.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VTAK cumulative revenue shifted +0.0% while CLPT shifted +300.0%. In operating R&D and SG&A reinvestment, VTAK deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CLPT.

CLPT screens cheaper on headline valuation multiples. VTAK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (unreported EBITDA margin), whereas CLPT trades at 12.1x Forward P/E, 12.1x Trailing P/E, 0.60x PEG, and 6.6x EV/Revenue (-73.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VTAK (-111.3% ROE) versus CLPT (-167.5% ROE) capital efficiency.

In options market volatility and institutional positioning, VTAK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.19β · 76% Vol realized risk). By comparison, CLPT carries 68.7% implied volatility (2nd %ile, Compressed (<25th %ile)), a 1.17x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.90β · 85% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.